Serum levels of VEGFR2 have previously been evaluated in lung cancer with conflicting results; one study has reported higher [34] and one study - in agreement with our study - demonstrated lower levels [35] in NSCLC compared to controls. This evidence concerns the gene KDR and non-small cell lung carcinoma.